Growing Organ Failure Rate Favours Transplant Diagnostics Industry

transplant diagnostics blog:

The transplant diagnostics industry is expected to expand quickly in the years to come. By 2030, the transplant diagnostics market is projected to be worth USD 7.42 billion, growing at a CAGR of roughly 7.8%. This is due to both the rapid development of medical technology and the increased incidence of organic failures among the world's population.

Transplant diagnostics is a term used to describe a diagnostic process typically performed before and after transplantations. It aids in the analysis of the patient's medical circumstances. If HAIs are not prevented, the person with low immunity bears the chance of contracting them, which could be fatal. Healthcare professionals and laboratory experts work harmoniously during the operation to ensure better patient results.

When an organ such as the liver, pancreas, lungs, kidney, or heart fails, it may be necessary to transplant it. The antigens on the surface of human leukocytes control body recognition and prevent the body from rejecting transplants of alien tissue. The genes on chromosome six regulate a complex known as the major histocompatibility complex in humans. In organ and bone marrow transplants, diagnostic human leukocyte antigen (HLA) testing is carried out to ascertain the tissue compatibility between the donor and recipient.

Market Insights

An increase in the number of people with chronic illnesses that frequently cause organ failure is driving up the demand for transplant surgeries. Personalized medicine and stem cell therapy are also becoming more popular, expanding the transplant diagnostics industry.  

Among the key transplant diagnostics industry trends, the expansion of financing for research and development institutes will help aid in the worldwide market's strength during the predicted period. Additionally, the value of the transplant diagnostics market is projected to increase due to the growing senior citizen population. In contrast, the high costs of PCR and NGS instruments will likely restrain market expansion throughout the projection period.

According to the transplant diagnostics industry analysis, the molecular assay category is anticipated to account for the biggest market share. In 2020, the molecular assay market was expected to rule. Clinicians' preference for the molecular assay is credited with the segment's rise. Additionally, preferences for HLA typing by serologic detection are gradually changing due to benefits like accuracy, efficacy, and low risk. Today, PCR-based tests hold the largest market share for various applications. For instance, numerous techniques, like real-time PCR, digital PCR, and next-generation sequencing-based approaches, have been suggested for cfDNA analysis. To improve the droplet digital PCR (ddPCR)-based technique to quantify relative dd-cfDNA in plasma from kidney transplant (KTx) patients, a special pilot set of tests was conducted on single-nucleotide polymorphisms with a high potential to identify cfDNA from two individuals. The assays can precisely measure minor allele frequencies when analyzing 165 ng of human DNA.

Covid 19 Impact

The COVID-19 pandemic has slightly influenced healthcare systems and the transplant diagnostics industry. Organ donation can result in the acquisition of COVID-19 with a low risk of infection. Donors were examined for COVID-19 symptoms and exposure history. Living donors were typically required to wait 14 to 28 days before donating if they have visited high-risk areas or have come into contact with someone who has been identified as having COVID-19 infection or was undergoing testing for it. Some organizations that handle organ procurement tested some or all donors for COVID-19.

Additionally, patients with post-transplant or other high-risk conditions may be more susceptible to developing a severe COVID-19 infection since transplant recipients are more likely to contract viruses like the flu or the common cold and are taking immunosuppressive medications.

Modern developments

• Immucor, Inc., a transfusion and transplantation diagnostics company, announced the addition of two new products to its transplant diagnostics portfolio in March 2022, proving its continuous dedication to innovative developments in the histocompatibility sector.